



Atty.
Dkt. No.

M#

Client Ref.

037003-0307430

1991-30-0020CP3C3

Applicant: RAYCHAUDHURI et al.

Appln. No.: 10/743,398

Filing Date: December 23, 2003

Date: May 21, 2004

Page 1 of 3

Examiner: Unassigned

4:11

Group Art Unit:
1853 1648

U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date if appropriate
WV	AR	3,083,142	03/1963	Howell			
	BR	3,790,665	02/1974	Glass			
*	CR	3,919,411	11/1975	Glass			
*	DR	4,053,585	05/1976	Allison			
*	ER	4,117,113	11/1977	Allison			
*	FR	4,770,874	09/1988	Allison			
*	GR	4,772,466	09/1988	Allison			
*	HR	4,778,784	10/1988	Dreesman			
	IR	4,877,611	10/1989	Cantrell			
*	JR	4,963,354	06/1990	Shepard			
	KR	5,114,708	05/1992	Hunter			
	LR	5,234,683	08/1993	Hunter			
*	MR	5,585,103	12/1996	Raychaudhuri			
*	NR	5,695,770	12/1997	Raychaudhuri			
WV	OR	5,709,860	01/1998	Raychaudhuri			
*	PR	6,270,769	08/2001	Raychaudhuri			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
WV	QR	0135376	03/1995	EP					
*	RR	0171496A2	2/1986	EP					
*	SR	0382271	08/1990	EP					
*	TR	0399843	11/1990	EP					
*	UR	0498767A2	8/1992	EP					
*	VR	0451216 B1	10/1991	EP					
*	WR	0460674A2	12/1991	EP					
*	XR	0682040 A1	11/1995	EP					
*	YR	WO 88/02634	4/1988	PCT					
*	ZR	WO 90/14837	12/1990	PCT					
*	AAR	WO 92/06113	Apr 1992	PCT	Van Wijnendale et al.	X		X	
*	BBR	WO 92/11291	Jul 1992	PCT	Van Wijnendale et al.	X		X	
*	CCR	WO 92/16231	Oct 1992	PCT	Francotte et al.	X		X	
*	DDR	WO 99/13912 A	03/1999	PCT	Braslawsky				
*	EER	GB 9105992.3	Mar 1991	GB	SmithKline	X		X	

* References were cited and/or submitted during prosecution of U.S. Patent Nos.: 5,585,103 issued December 17, 1996; 6,270,769 issued August 7, 2001; 5,709,860 issued January 20, 1998; 5,695,770 issued December 9, 1997; 6,197,311 issued March 6, 2001; and U.S. Application No. 09/740,003, filed on December 20, 2000.

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
MA	FFR	Acres RB, et al., "Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen," <i>J Immunother</i> , 1993, 14: 136-43.	
*	GGR	Allison AC, et al., "An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity," <i>J Immunol Methods</i> , 1986, 95:157-68.	
*	HHR	Allison AC, et al., "Vaccines: recent trends and progress," <i>Immunol Today</i> , 1990, 11: 427-9.	
*	IIR	Allison et al., <i>Vaccines 87</i> , Cold Spring harbor Laboratory (1987).	
*	JJR	Allison et al., <i>Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and modulators of Non-Specific Resistance</i> , pp. 191-201, 1987.	
*	KKR	Allison, <i>Immunopotentialion</i> , Elsevier, Excerpta Medica, North-Holland, pp. 73-99, 1973.	
*	LLR	Allison, 1988, <i>Technological Advances in Vaccine Development</i> , pp. 401-409.	
*	MMR	Allison, "Non-Specific" Factors Influencing Host Resistance, pp. 247-258 (Karger, Basel 1973).	
*	NNR	Alwan WH, et al., "CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells," <i>Clin Exp Immunol</i> , 1992, 88: 527-36.	
*	OOR	Asherson GL, et al., "Production of delayed hypersensitivity by antigen associated with peritoneal exudate cells and the effect of pretreatment with Freund's complete adjuvant," <i>Immunology</i> , 1972, 22: 465-73.	
*	PPR	Berman LD, et al., "Effects of Freund's adjuvant on adenovirus oncogenesis and antibody production in hamsters," <i>Int J Cancer</i> , 1967, 2: 539-43.	
*	QQR	Brugh M, et al., "Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants," <i>Am J Vet Res</i> , 1983, 44: 72-5.	
*	RRR	Byars NE, et al., "Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity," <i>Vaccine</i> , 1987, 5: 223-8.	
*	SSR	Byars NE, et al., "Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation," <i>Vaccine</i> , 1990, 8: 49-56.	
*	TTR	Campbell MJ, et al., "Idiotypic vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits," <i>J Immunol</i> , 1987, 139: 2825-33.	
*	UUR	Campbell MJ, et al., "Idiotypic vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity," <i>J Immunol</i> , 1990, 145: 1029-36.	
*	VVR	Chemical and Physical Properties Emulsifiers, <i>Uniqema</i> , Paper FF/E/03-01/AMERI/14/500.	
*	WVR	Eppstein et al., <i>Advanced Drug Deliver Reviews</i> , 4:233-253, 1990.	
*	XXR	Ghossein RA, et al., 1995, "Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications," <i>J Clin Oncol</i> , 13(5):1195.	
*	YYR	Goldstein et al., Chapter 4, <i>mAbs To Human Lymphocyte Surface Antigens</i> , p. 71.	
*	ZZR	Harada, M. et al., 1994, "Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2," <i>Cancer Immunol Immunother</i> , 38:332-338.	
*	AAAR	Horiguchi Y, et al., 2002, "Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes," <i>Clin Cancer Res</i> , 8(12):3885-3892.	
*	BBBBR	Hunter R, et al., "Mechanisms of action of nonionic block copolymer adjuvants," <i>Aids Research and Human Retroviruses</i> , 1994, 10(2):595-8.	
*	CCCR	Hunter R, et al., "The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance," <i>J Immunol</i> , 1981, 127:1244-50.	
*	DDDR	Hunter RL, et al., "The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers," <i>J Immunol</i> , 1984, 133: 3167-75.	
*	EEER	Hunter R, et al., "Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody," <i>Vaccine</i> , 1991, 9:250-6.	
*	FFFR	Ioannides C.G. and Whiteside T.L., 1993, "Short Analytical Review: T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of Cancer," <i>Clinical Immunology and Immunopathology</i> , 66(2):91-106.	
*	GGGR	Israeli RS, et al., 1993, "Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen," <i>Cancer Res</i> , 53(2):227-230.	
*	HHHR	Kahn M, et al., "CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen," <i>J Immunol</i> , 1991, 146:3235-41.	
*	IIIR	Kenney JS, et al., "Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies," <i>J Immunol Methods</i> , 1989, 121: 157-66.	
*	JJJR	Khusmith S, et al., "Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein," <i>Science</i> , 1991, 252: 715-8.	
*	KKKR	Kimura J, et al., "Studies on the adjuvant effect of water-in-oil-in-water (w/o/w) emulsion of sesame oil. 1. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion," <i>Jpn J Exp Med</i> , 1978, 48:149-54.	
*	LLLR	Kolata, New York Times.	

* References were cited and/or submitted during prosecution of U.S. Patent Nos. 5,585,103 issued December 17, 1996; 6,270,769 issued August 7, 2001; 5,709,860 issued January 20, 1998; 5,695,770 issued December 9, 1997; 6,197,311 issued March 6, 2001; and U.S. Application No. 09/740,003, filed on December 20, 2000.

MMMR	Korstvedt, H. et al., 1984, <i>Drug Cosmet Ind</i> , 135, 36-37.
NNNR	Kwak LW, et al., "Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived Idiotype immunoglobulin," <i>Blood</i> , 1990, 76: 2411-7.
OOOR	Kwak et al., "Idiotype vaccination for patients with B-cell lymphoma," <i>Idiotype Networks in Bio and Med.</i> , 1990 Elsevier Sci. Pub. B.V., 163-171.
PPPR	Lee et al., Surfactant Effect on the Stability and Electroheological Properties of Polyaniline Particle Suspension, <i>Jour. Of Colloid & Interface Science</i> , 206, 424-438 (1998), CS985661.
QQQR	Letvin et al., <i>Vaccines 87</i> , Cold Spring harbor Laboratory (1987).
RRRR	Lidgate, D.M., et al., 1989, <i>Biopharm</i> , 2:28-32.
SSSR	Maa et al., "Performance of Sonication and Microfluidization for Liquid-Kiquid Emulsification," <i>Phar. Dev & Tech.</i> , 4(2), 233-240 (1999).
TTTR	Mackewicz CE, et al., "CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual," <i>J Clin Invest</i> , 1991, 87: 1462-6.
UUUR	McLaughlin, JP, et al., 1996, "Improved Immunotherapy of a Recombinant Carcinoembryonic Antigen Vaccinia Vaccine When Given in Combination with Interleukin-2," <i>Cancer Research</i> , 56:2361-2367.
VVVR	Mitchell MS, et al., "Active-specific immunotherapy for melanoma," <i>J Clin Oncol</i> , 1990, 8: 856-69.
WWWR	Morein et al., <i>Immunological Adjuvants and Vaccines</i> , Plenum Press, Published in cooperation with NATO Science Affairs Division, pp. 153-161.
XXXR	Morgan AJ, et al., "Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use," <i>J Med Virol</i> , 1989, 29: 74-8.
YYVR	Murphey-Corb M, et al., "A formalin-inactivated whole SIV vaccine confers protection in macaques," <i>Science</i> , 1989, 246: 1293-7.
ZZZR	Nicholas JA, et al., "Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication," <i>Virology</i> , 1991, 182: 664-72.
AAAAR	Peace DJ, et al., "Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein," <i>J Immunother</i> , 1993, 14: 110-4.
BBBBR	Phillips NC, et al., "Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma," <i>Cancer Detect Prev</i> , 1990, 14: 491-6.
CCCCR	Rennie, <i>Scientific American</i> , Jul. 1991, p. 24.
DDDDR	Rickman LS, et al., "Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalene in malaria circumsporozoite protein vaccine," <i>Lancet</i> , 1991, 337: 998-1001.
EEEEER	Sanchez-Pescador L, et al., "The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine," <i>J Immunol</i> , 1988, 141: 1720-7.
FFFFR	Sanda MG, et al., "Molecular characterization of defective antigen processing in human prostate cancer," <i>J Natl Cancer Inst</i> , 1995, 87: 280-5.
GGGGR	Shen L, et al., "Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes," <i>Science</i> , 1991, 252: 440-3.
HHHHR	Staerz UD, et al., "Cytotoxic T lymphocytes against a soluble protein," <i>Nature</i> , 1987, 329: 449-51.
IIIIIR	Stover CK, et al., "New use of BCG for recombinant vaccines," <i>Nature</i> , 1991, 351: 456-60.
JJJJR	Takahashi H, et al., "An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes," <i>Proc Natl Acad Sci U S A</i> , 1988, 85: 3105-9.
KKKKR	Takahashi H, et al., "Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs," <i>Nature</i> , 1990, 344: 873-5.
LLLLR	Takayama K, et al., "Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by popolysaccharides, lipid A and precursors," <i>Vaccine</i> , 1991, 9: 257-65.
MMMMR	Tsang, D.Y., et al., 1995, "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From patients Immunized with Recombinant Vaccinia-CEA Vaccine," <i>J of the Nat'l Cancer Inst.</i> , 87(13):982.
NNNNR	WALKER et al., "Priming of Cytotoxic T Lymphocyte Responses with Recombinant HIV Envelope Proteins in Murine and Primate Models," <i>Humana Colloque Des Cent Gardes</i> , 1993, 321-325.
OOOOR	Wraith DC, et al., "Induction of Influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/ haemagglutinin preparation," <i>J Gen Virol</i> , 1985, 66 (Pt 6): 1327-31.
PPPPR	Xue, BH, et al., 1997, "Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen," <i>Prostate</i> , 30(2):73-78.
QQQQR	Yin et al., 1993, <i>Leukemia</i> 7 Suppl 2 527-30.

Examiner

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.